Core Viewpoint - China Antibody-B (03681) has received approval from the National Medical Products Administration (NMPA) for its innovative treatment product SM17, expanding its application from atopic dermatitis (AD) to inflammatory bowel disease (IBD), which includes Crohn's disease (CD) and ulcerative colitis (UC), addressing significant unmet medical needs [1] Group 1 - China Antibody-B's stock rose over 5%, currently trading at 2.1 HKD with a transaction volume of 9.53 million HKD [1] - The IND approval for SM17 marks a significant milestone in the company's development strategy, allowing for the treatment of chronic and debilitating diseases [1] - The company has completed follow-up for the Phase I bridging study of SM17 in healthy volunteers, with data supporting the advancement to Phase II clinical development for IBD [1] Group 2 - In addition to advancing the IND, SM17 is undergoing a bridging study to transition from intravenous to subcutaneous administration, expected to be completed in the first quarter of this year [1] - The company anticipates initiating Phase II clinical trials for AD in the second quarter of this year [1] - The expansion of SM17's indications from AD to IBD represents a significant clinical and commercial opportunity in a field with substantial unmet medical needs [1]
港股异动 | 中国抗体-B(03681)午前涨超5% 预计最早于二季度启动针对SM17 AD的II期临床试验